Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 3/20 | 0.39 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | CCNC | P24863 | 2/20 | 0.33 |
| ▸ | CDK8 | P49336 | 2/20 | 0.33 |
| ▸ | HASPIN | Q8TF76 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 2/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.31 |
| ▸ | KDM5A | P29375 | 2/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.31 |
| ▸ | MITF | O75030 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | REN | P00797 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 2/20 | 0.30 |
| ▸ | KDM4A | O75164 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1763903 | 0.82 | DYRK1A (0.35) | DYRK1ACYP19A1KMT2AALDH1A1MAPT | |
| SCHEMBL7063087 | 0.80 | DYRK1A (0.34) | DYRK1ACYP19A1HASPINLMNASMN1; SMN2 | |
| SCHEMBL1763382 | 0.77 | KDM5A (0.39) | DYRK1ACYP19A1LMNAKDM4CKDM5A | |
| SCHEMBL1737822 | 0.74 | MAPT (0.47) | DYRK1ARXFP1HASPINLMNASMN1; SMN2 | |
| SCHEMBL7063136 | 0.72 | KDM4E (0.33) | DYRK1ACYP19A1CCNCCDK8KDM4C | |
| SCHEMBL1763552 | 0.71 | ADRA2A (0.33) | — | |
| SCHEMBL7058849 | 0.70 | KDM5A (0.45) | SMN1; SMN2KDM5AALDH1A1RAB9AKDM5B | |
| SCHEMBL7058474 | 0.70 | AURKA (0.42) | ALDH1A1RAB9AMAPT | |
| SCHEMBL2628866 | 0.70 | KDM4C (0.44) | DYRK1ARXFP1CYP19A1LMNASMN1; SMN2 | |
| SCHEMBL1763079 | 0.70 | KMT2A (0.35) | RXFP1LMNASMN1; SMN2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | VIIV HEALTHCARE UK (NO. 4) LIMITED (GB) | 2016-03-17 | — | — | US | disclosed |
| US-20050261296-A1 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2005-11-24 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075703-A1 | SUBSTITUTED AZAINDOLEOXOACETIC PIPERAZINE DERIVATIVES | ITPA, IDO1, IDO2 | DYRK1A 4382/4885RXFP1 4813/4885CYP19A1 1495/4885 |
| US-20050261296-A1 | Viricides, immunomodulators or HIV entry inhibitors; lymphadenopathy associated virus, human T-cell leukemia/lymphoma virus; AIDS | MALT1, BCL6, CD4 | DYRK1A 3663/4885RXFP1 4883/4885CYP19A1 1955/4885 |
| US-20030181463-A1 | Antiviral azaindole derivatives | ZC3HAV1, MAVS, AZI2 | DYRK1A 3956/4885RXFP1 4719/4885CYP19A1 2438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.